ProCE Banner Activity

CME

Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience

Multimedia

Watch this on-demand webcast of a live CCO webinar where an expert panel discusses the optimal use of pediatric asparaginase regimens in the treatment of AYA and adult patients with ALL, including patient case discussions and practical guidance on strategies to support completion of therapy.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 24, 2022

Expiration: January 23, 2023

No longer available for credit.

Share

Faculty

Wendy Stock

Wendy Stock, MD

Professor of Medicine
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Emily Curran

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Dan Douer

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Scott Howard

Scott Howard, MD, MSc

Professor
Department of Acute and Tertiary Care
The University of Tennessee Health Science Center
Memphis, Tennessee

Stephen P. Hunger

Stephen P. Hunger, MD

Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Jazz Pharmaceuticals

Servier Oncology Global Medical and Patient Affairs

Servier Pharmaceuticals

Target Audience

This program is intended for hematologists/oncologists and other health professionals that care for patients with acute lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select asparaginase-based induction treatment for adolescent/young adult and adult patients, considering optimal dosing and treatment schedules
  • Identify clinical and silent hypersensitivity reactions to asparaginase therapies
  • Plan strategies to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate expert recommendations and available data on re-exposure of currently available asparaginase treatments or recombinant asparaginase formulations
  • Consider the data and clinical experience in pediatric patients to aid in treatment decisions for adolescent/young adult and adult patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Wendy Stock, MD

Professor of Medicine
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Wendy Stock, MD, has disclosed that she has received consulting fees from Agios, Amgen, AstraZeneca, GlaxoSmithKline, Jazz, Kite, Kronos, Kura, MorphoSys, Newave, Pfizer, Pluristem, Servier, and Syndax and honoraria from Jazz and Pfizer.

Faculty Disclosure

Primary Author

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Emily Curran, MD, has disclosed that she has received consulting fees from Amgen, Servier, and Tempus.

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Dan Douer, MD, has disclosed that he has received consulting fees from Amgen, Jazz, and Servier and fees for non-CME/CE services from Adaptive, Amgen, and Servier.

Scott Howard, MD, MSc

Professor
Department of Acute and Tertiary Care
The University of Tennessee Health Science Center
Memphis, Tennessee

Scott Howard, MD, MSc, has disclosed that he has received consulting fees from Cellworks, Sanofi, and Servier and fees for non-CME/CE services from Sanofi.

Stephen P. Hunger, MD

Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Stephen P. Hunger, MD, has disclosed that he has received consulting fees from Servier and has ownership interest in Amgen.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Lisa Kuhns, PhD

Lisa Kuhns, PhD, has disclosed that she has received other financial or material support from Alcresta Therapeutics, Primus Pharmaceuticals, Parnell Pharmaceuticals, bioMerieux, and Beckman Coulter.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2022, through January 23, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging asparaginase therapies for treatment of acute lymphoblastic leukemia in young adolescent and adult patients.